Skip to content
superstack
Draft entry. Written from the cited papers but not yet reviewed by a person. Check the references before relying on any claim.

Saffron

also Crocus sativus · Croci stigma · affron · Safr'Inside · Saffr'activ

Saffron is the dried stigma of Crocus sativus; supplements usually contain extracts with several constituents rather than a single molecule [1]. Human trials suggest benefits for mood and subjective sleep quality, but a 2026 meta-analysis found improvements on self-rated depression and anxiety scales without significant effects on Hamilton depression or anxiety ratings or overall mood scores [2]. Results depend on the preparation and outcome measured [3][4]. Trials of the branded extract affron mostly report modest gains on self-rated depression scores, but a 2021 EFSA review judged its mood evidence insufficient for a health claim [5][6].

A plausible mood and sleep supplement with human trial evidence, inconsistent outcomes and extract-specific doses.

A plant extract; no single structure to draw.
Human RCTs34 papers · 2004–2026 · 30 journals · 22 in humans
  • meta-analysis
  • RCT
  • trial
  • observational
  • preclinical / case
  • review / patent / other
  • retracted
2004 · RCT · Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].2012 · preclinical · Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive-compulsive disorder.2016 · review · A simple practice guide for dose conversion between animals and human.2016 · patent · Use of a new saffron extract for the prevention of mood disorders related to depression2017 · RCT · affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial.2018 · RCT · affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study.2019 · meta-analysis · Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis.2019 · meta-analysis · The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis.2019 · RCT · Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study.2020 · clinical trial · Bioaccessibility and Pharmacokinetics of a Commercial Saffron (Crocus sativus L.) Extract.2020 · RCT · Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial.2020 · meta-analysis · Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials.2020 · preclinical · Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract.2021 · RCT · Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial.2021 · review · Affron® and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.2021 · RCT · The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study.2021 · RCT · An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study.2021 · RCT · Impact of saffron (Crocus Sativus Linn) supplementation and resistance training on markers implicated in depression and happiness levels in untrained young males.2021 · preclinical · Saffron Extract-Induced Improvement of Depressive-Like Behavior in Mice Is Associated with Modulation of Monoaminergic Neurotransmission.2021 · preclinical · Prevention of Stress-Induced Depressive-like Behavior by Saffron Extract Is Associated with Modulation of Kynurenine Pathway and Monoamine Neurotransmission.2021 · preclinical · Saffron (Crocus Sativus L.), Combined with Endurance Exercise, Synergistically Enhances BDNF, Serotonin, and NT-3 in Wistar Rats.2022 · RCT · An examination into the mental and physical effects of a saffron extract (affron®) in recreationally-active adults: A randomized, double-blind, placebo-controlled study.2022 · preclinical · Circulating Human Serum Metabolites Derived from the Intake of a Saffron Extract (Safr'InsideTM) Protect Neurons from Oxidative Stress: Consideration for Depressive Disorders.2022 · preclinical · Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach.2022 · case report · Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: A Case Report.2023 · preclinical · Saffron extract interferes with lipopolysaccharide-induced brain activation of the kynurenine pathway and impairment of monoamine neurotransmission in mice.2023 · preclinical · Effects of Saffron Extract (Affron®) with 100 mg/kg and 200 mg/kg on Hypothalamic-Pituitary-Adrenal Axis and Stress Resilience in Chronic Mild Stress-Induced Depression in Wistar Rats.2023 · preclinical · Effects of Supplementation with the Standardized Extract of Saffron (affron®) on the Kynurenine Pathway and Melatonin Synthesis in Rats.2025 · RCT · Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial.2025 · RCT · An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial.2025 · RCT · Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans.2026 · meta-analysis · Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials.2026 · RCT · The effects of a saffron extract (Affron®) on mood, sleep, self-esteem, and exploratory measures of physical appearance in women aged 50 to 70 years experiencing low mood and poor sleep: a randomised, double-blind, placebo-controlled trial.2026 · meta-analysis · Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence.
in its favor
  • + Some pooled analyses find lower self-reported depression and anxiety scores
  • + Several short trials report better subjective sleep quality
watch for
  • − Clinician-rated mood results are inconsistent
  • − Extracts and their standardization measures are not interchangeable
  • − Most affron trials share one lead investigator and manufacturer funding or product
  • − Gastrointestinal symptoms and occasional palpitations have been reported

Saffron is a botanical mixture studied chiefly for mood and sleep. A 2019 review of 23 trials found pooled depression and anxiety benefits, but detected publication bias and limited regional diversity [7]. A separate eight-study analysis found no significant difference from fluoxetine; its placebo estimate had a confidence interval reaching zero and substantial heterogeneity. Failure to detect a difference in small trials does not establish antidepressant equivalence [8].

The 2026 GRADE-assessed review included 34 randomized trials and 1,769 adults. Beck Depression Inventory and Beck Anxiety Inventory scores improved, with substantial heterogeneity (I² above 90%). Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and Profile of Mood States outcomes did not improve significantly. The authors rated certainty moderate, but this split makes a broad claim of reliable antidepressant efficacy premature [2].

Adjunctive evidence is mixed too. In an eight-week affron trial alongside existing antidepressants, clinician-rated depressive symptoms improved more than placebo, while the self-rated depression scale did not. Quality of life and baseline-adjusted antidepressant side-effect outcomes also showed no significant advantage [9].

affron mood trials: In the first, 128 adults with self-reported low mood took 22 or 28 mg/day for four weeks. At 28 mg/day, Profile of Mood States total mood disturbance and DASS-21 depression, anxiety and stress scores improved more than on placebo. The 22 mg/day arm did not separate from placebo, and no formal dose-response analysis was presented [6][10]. In 80 adolescents aged 12 to 16, eight weeks of 14 mg twice daily improved self-rated separation anxiety, social phobia and depression. Parents' ratings mostly did not agree, and comparisons at individual time points were not significant [6][11].

In 86 perimenopausal women, 12 weeks of 28 mg/day missed significance on the primary outcome, the Greene Climacteric Scale total, in the repeated-measures analysis (p = 0.078). The psychological subscale and negative affect improved more than on placebo; hot flushes, somatic symptoms and quality of life did not [12]. The largest affron trial randomized 202 adults with subclinical depressive symptoms to 28 mg/day or placebo for 12 weeks. DASS-21 depression fell 2.92 points more than on placebo (Cohen's d 0.39), and 72.3% versus 54.3% improved by at least 7 points. The other secondary outcomes showed no between-group differences, and placebo responses were large [5]. A 2026 trial in 86 women aged 50 to 70 with low mood and poor sleep found a 2.37-point DASS-21 depression advantage (d 0.48; 48.8% versus 25.6% responders). Self-esteem and sleep-related impairment also improved, as exploratory outcomes; sleep disturbance, self-rated appearance and AI-estimated skin age did not [13].

Not every affron trial was positive. In 62 recreationally active adults taking 28 mg/day for six weeks, exercise enjoyment (the primary outcome), mood, wearable-measured sleep, heart rate variability and blood BDNF, neuropeptide Y and oxytocin showed no between-group differences. Gains in exercise enjoyment and heart rate variability appeared only in an exploratory analysis of the men [14].

Regulatory review and funding: In 2021 the EFSA nutrition panel rejected the manufacturer's application for a "healthy mood" health claim. It accepted that the four-week adult trial showed an effect at 28 mg/day but noted the result had not been replicated. It could draw no conclusions from the adolescent trial, set aside the adjunctive trial because its participants were taking antidepressants, and found no reliable evidence of a mechanism in humans [6]. The 2025 and 2026 trials post-date that opinion. Every affron efficacy trial cited here except the first was led by the same investigator [5][9][11][12][13][14][15][16]. Pharmactive, which makes affron, funded the 2017, 2018, 2021 sleep and 2025 trials and supplied the extract for the perimenopause and exercise trials [5][10][11][12][14][16].

Sleep: A four-week affron trial improved insomnia severity, restorative sleep and diary-rated sleep quality, without significant improvement in diary-measured sleep duration or latency [15]. A 120-person follow-up gave 14 or 28 mg once, an hour before bed, for 28 days. Sleep-quality ratings (the primary outcome), mood on waking and Insomnia Symptom Questionnaire scores improved more than on placebo, and the two doses performed similarly. Other diary and questionnaire outcomes did not differ, and questionnaire data came from 102 of the 120 participants. Evening salivary melatonin rose while cortisol did not change [16]. In the six-week Saffr'activ trial, actigraphy showed more time in bed, without significant improvement in total sleep time or sleep efficiency; several questionnaire improvements were within-group changes rather than clear advantages over placebo [3].

A 2025 Safr'Inside trial found a modest insomnia-score advantage when the two saffron arms were pooled. The separate 20 mg and 30 mg comparisons on that primary outcome were not significant after multiple-comparison adjustment. Subjective sleep quality and stress improved, while daytime sleepiness, positive/negative affect and quality of life did not [4].

Cognition: A review of four small trials in Alzheimer's disease or mild cognitive impairment found some cognitive-scale benefits, but insufficient evidence for clinical recommendations. Daily-living improvements were not significant, and these patient studies do not establish memory enhancement in healthy adults [17].

Crocins, crocetin, safranal and picrocrocin are among saffron's constituents. Crocins are glycosides that can be converted to circulating crocetin; their presence in an extract does not imply that unchanged crocin reaches the human brain [1].

Proposed mood and sleep mechanisms include changes in serotonin, GABA and glutamate signaling, with antioxidant and anti-inflammatory pathways also discussed. These explanations come largely from constituent, cell and animal work. Human sleep trials measure outcomes rather than demonstrating a particular receptor mechanism, so saffron should not be described as a clinically established serotonin-reuptake inhibitor or GABA agonist [3].

Serotonin — human evidence: None of the human studies cited here measured brain serotonin or serotonin transporter binding. In the six-week resistance-training trial, blood serotonin rose in both groups, by a reported 1.7 ng/mL with 150 mg/day saffron and 1 ng/mL with placebo, while tryptophan did not change. The abstract describes a greater change with saffron but gives no between-group test, the full text was paywalled, and the training itself raised serotonin [18]. In an ex vivo study, eight healthy men each gave blood before and 90 minutes after a single 300 mg Safr'Inside dose (the crocetin peak), about ten times the usual daily trial dose. Cultured human neuroblastoma cells (SH-SY5Y, differentiated to a neuron-like state) exposed to the post-dose serum released more serotonin and expressed less SERT mRNA than cells given each man's pre-dose serum. Under hydrogen-peroxide stress, the post-dose serum also prevented the fall in serotonin release and the rises in SERT mRNA and in the breakdown product 5-HIAA. This shows that circulating saffron metabolites can act on serotonin-handling cells in a dish, not that the same happens in the brain; the extract's manufacturer employed several of the authors [19].

Serotonin — animal evidence: Three mouse studies from one Bordeaux group, co-authored by employees of Safr'Inside's maker, used 6.25 mg/kg by mouth, which the authors scaled from 30 mg/day in people (human equivalent ≈0.51 mg/kg) [20][21]. After four weeks of daily dosing in unstressed mice, serotonin and 5-HIAA levels in the frontal cortex, striatum and hippocampus did not change. Hippocampal SERT mRNA fell, but SERT protein and uptake were not measured. A single dose also increased swimming in the forced swim test, the pattern typical of SSRIs, though the retest after chronic dosing was not significant and anxiety-like behavior did not change [20]. Given before four hours of restraint stress, one dose prevented the stress-induced rise in hippocampal SERT mRNA and in frontal-cortex 5-HIAA and serotonin turnover. Hippocampal serotonin turnover still rose, and SERT and 5-HT1A receptor protein did not differ from untreated stressed mice [22]. Given before an inflammatory LPS challenge, it kept hippocampal 5-HIAA from rising significantly above control levels, but did not prevent the striatal 5-HIAA rise or the increase in the serotonin-degrading enzyme MAO-A [23].

Other rodent work points the same way, with caveats. In mice under chronic stress, the saffron carotenoid crocetin raised hippocampal serotonin and tryptophan and serum serotonin, and lowered hippocampal SERT and IDO1 (which diverts tryptophan away from serotonin); the full text was paywalled, so the dose is not given here [24]. In rats given 40 mg/kg/day of a saffron extract for eight weeks (human equivalent ≈6.5 mg/kg), hippocampal serotonin did not rise with saffron alone, though 5-HIAA and the 5-HIAA/serotonin ratio did. Serotonin rose only when saffron was combined with treadmill training, by about 5% over controls [21][25]. In rats, injected crocins (30 and 50 mg/kg) reduced excessive grooming triggered by the serotonin-receptor agonist mCPP without changing grooming on their own; grooming stayed above control levels. That points to an interaction with serotonin-receptor-driven behavior, not a measured receptor effect [26].

Dopamine — human evidence: A small randomized trial had 28 young untrained men complete six weeks of resistance training with either 150 mg/day pure saffron or placebo. Blood dopamine increased by a reported 0.7 ng/mL in the saffron group, while the placebo group showed no significant change. This was a blood measurement during a combined exercise intervention, not a demonstration of increased brain dopamine or dopamine-reuptake inhibition. The reported within-group significance also does not, by itself, establish a significant difference between groups [18].

Dopamine — animal evidence: In a 2021 mouse study, oral Safr'Inside at 6.25 mg/kg before acute restraint stress prevented the stress-associated rise in striatal homovanillic acid (HVA) and the HVA/dopamine ratio, a measure of dopamine turnover. Whole-tissue dopamine concentrations did not significantly change. D1 receptor protein levels fell in the frontal cortex and striatum, while dopamine transporter (DAT) levels were unchanged; these findings describe modulation of dopamine metabolism and signaling rather than a uniform dopamine increase [22].

In a 2025 chronic-stress rat study, repeated injected saffron extract at 40 mg/kg/day restored the reward-triggered phosphorylation of DARPP-32 in the nucleus accumbens and medial prefrontal cortex. This is a downstream marker of D1-related signaling: the authors inferred improved dopamine responsiveness, rather than directly measuring dopamine release. Motivation to work for sucrose improved in the later progressive-ratio test, but earlier fixed-ratio performance remained impaired. The same paper included a small human depression trial, which collected no dopamine biomarkers; its symptom results therefore do not establish the proposed brain mechanism in people [27].

affron in rats: In socially isolated rats, 200 mg/kg affron by mouth (human equivalent ≈32 mg/kg) for 21 days increased sucrose preference and escape swimming and climbing in the forced swim test. It did not reduce immobility or change anxiety measures in the elevated plus maze, and 50 mg/kg injected into the abdomen had no effect [21][28]. In rats under chronic mild stress, three weeks of 100 or 200 mg/kg by mouth (≈16–32 mg/kg human equivalent) lowered hypothalamic vasopressin and CRF and preserved hypothalamic BDNF. Only 200 mg/kg restored some sucrose preference, and the falls in corticosterone did not reach significance [21][29]. One week of 150 mg/kg by mouth before the rest period (≈24 mg/kg human equivalent) raised serum melatonin, lowered serum kynurenine and increased pineal expression of AANAT, the rate-limiting enzyme for melatonin [21][30]. That fits the evening melatonin rise in the human sleep trial but does not show the same pathway operates in people [16]. All of these rodent doses are far above the 28 mg/day, about 0.4 mg/kg for a 70 kg adult, used in the human trials [5].

Downstreamconsequences of that action, not targets of their own
  • Serotonin transporter (SERT) expression and serotonin turnovermodulates
    In mice, a Safr'Inside dose scaled from human use lowered, or prevented rises in, hippocampal SERT mRNA and blunted stress- or inflammation-induced serotonin turnover without changing brain serotonin levels. Serum taken from people after a 300 mg dose raised serotonin release from cultured neuron-like cells. SERT inhibition or occupancy in the human brain has not been shown [19][20][22][23]
    unclear
  • GABA-related signalingmodulates
    Proposed from constituent and preclinical research; human sleep trials do not establish receptor engagement [3]
    unclear
  • Dopamine signalingmodulates
    Animal studies report changes in dopamine metabolism and reward-related signaling; a small exercise trial measured blood dopamine rather than brain dopamine [18][22][27]
    unclear
  • Melatonin synthesismodulates
    An evening affron dose raised evening salivary melatonin in poor sleepers; in rats it raised serum melatonin and pineal AANAT expression while lowering kynurenine. The pathway has not been traced in people [16][30]
    unclear

Formulation

how the form changes blood levels

affron: A water extract of Spanish saffron stigmas, standardized to more than 3.5% "Lepticrosalides", the manufacturer's term for crocin isomers plus safranal [15][30]. EFSA's review gives a typical combined content of 3.5–3.9%, about 99.5% of it crocins, with dextrin as the carrier [6]. The 2026 trial specified 3.48% crocins and 0.03% safranal [13]. This is not a claim that the product contains 3.5% safranal. The manufacturer's Spanish patent claims a stigma-extract powder with 0.03–1% safranal and at least 3.48% crocins; that is a company filing, not peer-reviewed evidence. The rat work describes extraction in water below 70 °C [30][31]. Most affron trials used a 14 mg tablet twice daily; the 2021 sleep trial gave its dose once, an hour before bed [5][16].

Saffr'activ SAF 3C PIM: The six-week trial described a 15.5 mg preparation supplying 0.9 mg crocins and 0.7 mg safranal. Its measured constituent amounts differ from affron's combined standardization metric [3].

Safr'Inside: The 2025 trial used an extract specified as containing more than 3% crocins, 0.2% safranal, 1% picrocrocin derivatives and 0.1% kaempferol derivatives, assessed by U-HPLC [4]. Milligrams of one named preparation do not establish an equivalent dose of another.

Dosing

as studied or commonly reported; not a recommendation

Doses below are what studies used or, where marked, what is commonly reported. None is a recommendation.

Oral

  • 150 mg pure saffron pill
    28 young untrained men completed saffron or placebo alongside supervised resistance training four times weekly; blood dopamine and other markers were assessed
    once daily, immediately after resistance training or at the same time on non-training days · 6 weeks
    human study[18]
  • 10 mg dried ethanolic saffron stigma extract (30 mg/day)
    30 adults with mild-to-moderate major depression; pilot comparison with imipramine without a placebo arm
    three times daily · 6 weeks
    human study[32]
  • 14 mg affron extract (28 mg/day)
    63 adults randomized for self-reported poor sleep; 55 provided outcome data
    twice daily, with or without food · 28 days
    human study[15]
  • 15.5 mg Saffr'activ SAF 3C PIM preparation
    66 adults randomized with mild-to-moderate sleep complaints and anxiety; 59 in the per-protocol analysis
    once daily in the evening with water · 6 weeks
    human study[3]
  • 20 mg or 30 mg Safr'Inside extract (separate trial arms)
    165 adults randomized with moderate insomnia; 158 included in the baseline-data analysis
    once daily, approximately 60 minutes before bedtime · 4 weeks
    human study[4]
  • 56 mg or 84 mg affron extract
    13 healthy young adults; crocetin exposure, not an efficacy dose-finding trial
    single dose after overnight fasting, followed by breakfast · 24-hour pharmacokinetic sampling
    human study[1]
  • 300 mg Safr'Inside extract, one capsule
    8 healthy men donated serum for cell-culture experiments; about ten times the usual daily trial dose, and not an efficacy study
    single dose after a 12-hour fast; blood drawn at 90 minutes · single dose
    cell study[19]
  • 11 mg or 14 mg affron tablet (22 or 28 mg/day; separate trial arms)
    128 adults with self-reported low mood; only the 28 mg/day arm separated from placebo
    twice daily, with the morning and midday meals · 4 weeks
    human study[6][10]
  • 14 mg affron (28 mg/day)
    80 adolescents aged 12–16 with mild-to-moderate anxiety or depressive symptoms; 68 completed
    twice daily, with the morning and midday meals · 8 weeks
    human study[6][11]
  • 14 mg or 28 mg affron (separate trial arms)
    120 adults with unsatisfactory sleep; the two doses gave similar results
    once daily, 1 hour before bed · 28 days
    human study[16]
  • 14 mg affron (28 mg/day)
    86 perimenopausal women aged 40–60 with menopausal complaints; 82 in the analysis
    twice daily, morning and evening, with or without food · 12 weeks
    human study[12]
  • 14 mg affron (28 mg/day)
    62 recreationally active adults continuing their usual exercise; no between-group differences overall
    twice daily, with or without food · 6 weeks
    human study[14]
  • 14 mg affron (28 mg/day)
    202 adults aged 18–70 with subclinical depressive symptoms
    twice daily · 12 weeks
    human study[5]
  • 14 mg affron (28 mg/day)
    86 women aged 50–70 with low mood and self-reported poor sleep
    twice daily, morning and evening, with or without food · 12 weeks
    human study[13]
  • 6.25 mg/kg Safr'Inside (human equivalent ≈0.51 mg/kg)
    Male C57BL/6J mice in serotonin and dopamine studies; the authors scaled the dose from 30 mg/day in people. Animal doses, not tested in humans
    once daily by gavage, or a single dose before stress or an LPS challenge · single dose to 4 weeks
    animal study[20][21][22][23]
  • 100–200 mg/kg/day affron (human equivalent ≈16–32 mg/kg)
    Male Wistar rats in social-isolation, chronic-mild-stress and melatonin studies; animal doses, not tested in humans
    once daily by gavage or in drinking water · 1–3 weeks
    animal study[21][28][29][30]
Form
Trials use stigma extracts with different constituent profiles. The named preparations in the rows are part of the evidence, not substitutes for one another [3][4][15].
Timing and food
Evening dosing was used in the Saffr'activ and Safr'Inside sleep trials and in one affron sleep trial, which gave its dose an hour before bed [3][4][16]. Most other affron trials used a 14 mg tablet twice daily, with or without food [12][13][15].
Time to effect
Sleep outcomes were assessed over four to six weeks in these trials, and affron mood trials ran four to twelve weeks. In the perimenopause trial most of the self-rated mood improvement appeared in the first four weeks. A plasma metabolite peak does not establish when a clinical benefit starts [1][3][4][12][15].
Notes
These are reported study protocols, not dosing recommendations. The 56 and 84 mg single doses were used for pharmacokinetics, not evidence that higher doses improve mood or sleep [1]. The full text of the adjunctive antidepressant trial was unavailable at the publisher, so its additional administration details are not reproduced here [9]. The 150 mg exercise-study protocol comes from its abstract and publisher preview; the full text was paywalled. That preparation and combined exercise intervention do not establish an equivalent dose of a standardized extract [18]. The full texts of the 2017, 2018, 2021 sleep and 2025 affron trials were paywalled at the publisher. Their rows come from the abstracts, the publisher previews and EFSA's review, which reproduces the 2017 and 2018 protocols [5][6][10][11][16]. The rat doses are converted by body-surface-area scaling and were never tested in people [21].

Pharmacokinetics

what the body does with it
Half-lifeA 13-person affron study estimated a plasma crocetin half-life of 0.85 ± 0.04 hours after a single 56 or 84 mg extract dose. This describes the measured metabolite under that protocol, not the duration of a mood or sleep effect [1].
Time to peakPlasma crocetin peaked at 60 minutes after 56 mg affron and 90 minutes after 84 mg [1].
Peak levelMean plasma crocetin peaks were 0.26 ± 0.12 µg/mL after 56 mg affron and 0.39 ± 0.10 µg/mL after 84 mg [1].
BioavailabilityAbsolute human oral bioavailability was not measured. The roughly 41% crocin bioaccessibility reported in simulated digestion is not a human absorption percentage [1].
MetabolismCrocin glycosides are converted to crocetin before reaching the circulation; only crocetin was quantifiable in plasma in the cited extract study [1].

Safety

risks and cautions, not medical advice

Short studies generally report reasonable tolerability, but adverse events occur. The 2025 sleep trial recorded gastrointestinal discomfort in ten participants on 30 mg, six on 20 mg and four on placebo; no serious adverse events were reported [4]. One participant in the six-week Saffr'activ trial withdrew after evening palpitations that stopped when supplementation stopped [3].

Adverse events in the affron trials were mostly mild. The 12-week perimenopause trial logged 11 reports on saffron and 9 on placebo. Flatulence, nausea or bloating occurred only on saffron, and one participant withdrew for bloating [12]. Two participants in the six-week exercise trial reported more vivid dreams [14]. The 2025 and 2026 trials reported no serious adverse events [5][13]. In the adolescent trial, the only participant who reported tablet-related nausea and headaches was on placebo [6].

The early depression pilot recorded hypomania in two saffron participants and one imipramine participant, without a significant between-group difference. This is a signal to discuss in people with bipolar disorder or new mood activation, not an estimate of a causal risk [32].

A 2026 safety review found inconsistent adverse-event monitoring and substantial variation in preparations and duration. Small, short trials cannot reliably exclude rare harms, and pregnancy and breastfeeding safety remain inadequately characterized [33].

Adverse effects
reported, not universal
  • Gastrointestinal discomfort occurred more often in the saffron arms of the 2025 sleep trial [4]
  • One sleep-trial participant reported palpitations that resolved after stopping the preparation [3]
  • Headache, nausea and hypomania were recorded in the early depression pilot; the hypomania difference from imipramine was not significant [32]
  • Flatulence, nausea or bloating were reported only in the saffron arm of a 12-week perimenopause trial [12]
  • More vivid dreams were reported by two participants in a six-week affron exercise trial [14]
Cautions
who should think twice
  • Avoid unsupervised combination with anticoagulants; a bleeding case involved rivaroxaban, and antiplatelet combinations also warrant review [33][34]
  • Supplemental use during pregnancy or breastfeeding warrants avoidance without clinical guidance because safety data are limited [33]
  • Bipolar disorder or new hypomanic symptoms warrant clinical review; hypomania occurred in a small depression trial that excluded known bipolar disorder [32]
Limits of the evidence
what has not been shown
  • Self-rated mood benefits do not consistently match clinician-rated or overall mood outcomes [2][9]
  • Publication bias and limited regional diversity affect the depression literature [7]
  • Different preparations use different constituent profiles; doses cannot be assumed equivalent [3][4]
  • Better subjective sleep does not consistently mean more objectively measured sleep [3]
  • Dementia and mild cognitive impairment trials do not establish healthy-adult cognitive enhancement [17]
  • Small samples and inconsistent harm monitoring limit estimates of rare or long-term adverse effects [33]
  • Nearly all affron efficacy trials share one lead investigator and manufacturer funding or product, and EFSA found the mood evidence insufficient for a health claim in 2021 [5][6][12]
  • Large placebo responses in the biggest affron trial left a small between-group difference (d 0.39) [5]
  • Serotonin findings come from rodents, cultured cells and one blood measurement during an exercise trial; SERT changes were mostly in mRNA, not protein or uptake [18][19][20][22]

Interactions

documented pairs only, not exhaustive

Anticoagulants and antiplatelet medicines: A case report described nose and gum bleeding during concomitant rivaroxaban and saffron supplementation. One case cannot establish frequency or prove causality, but it supports avoiding an unsupervised combination. The safety review also calls for caution with antiplatelet medicines [33][34].

Antidepressants: Saffron has been tested as an adjunct under study conditions, with inconsistent benefits. That trial does not establish that every antidepressant combination is safe or effective; medication changes or adjunctive use need clinical review [9].

Is saffron as effective as an antidepressant?
Small comparisons have sometimes found no significant difference, but that does not establish equivalence. Pooled results differ by symptom scale, and adjunctive results are mixed [2][8][9].
Does saffron work like an SSRI?
Not in any demonstrated way. Mouse studies found lower hippocampal SERT mRNA and less stress-induced serotonin turnover without higher brain serotonin, and serum from people who took saffron raised serotonin release from cultured cells. SERT blockade has not been measured in people [19][20][22].
Can I substitute cooking saffron for a studied extract?
The cited protocols tested named extracts with specified constituent profiles. They do not establish an equivalent amount of culinary saffron or a different supplement [3][4][15].
Does saffron improve memory in healthy people?
The cognition review concerns Alzheimer's disease and mild cognitive impairment. It found insufficient evidence for clinical recommendations and cannot establish a memory benefit in healthy adults [17].
What does the affron research show?
In manufacturer-funded trials, 28 mg/day improved self-rated depression scores in adults with low mood over 4 to 12 weeks, with small-to-moderate effects and large placebo responses. Hot flushes, exercise outcomes and several sleep measures did not improve, and EFSA rejected a mood health claim in 2021 [5][6][12][13][14].

References

entry last reviewed 2026-09-26
  1. [1]
    Bioaccessibility and Pharmacokinetics of a Commercial Saffron (Crocus sativus L.) Extract.
    Almodóvar P, Briskey D, Rao A et al.Evid Based Complement Alternat Med 2020clinical trial · humanPMID 32089715◌ unreviewed
  2. [2]
    Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials.
    Mahmoudi R, Mohammadi-Sartang M, Servatyari K et al.Nutr Neurosci 2026meta-analysis · humanPMID 41693488◌ unreviewed
  3. [3]
    Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial.
    Pachikian BD, Copine S, Suchareau M et al.Nutrients 2021RCT · humanPMID 33925432◌ unreviewed
  4. [4]
    Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial.
    Schuster J, Mundhenke C, Nordsieck H et al.Sleep Med X 2025RCT · humanPMID 40698027◌ unreviewed
  5. [5]
  6. [6]
    Affron® and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.
    EFSA Panel on Nutrition, Novel foods and Food allergens (NDA), Turck D, Castenmiller J et al.EFSA J 2021review · humanPMID 34249157◌ unreviewed
  7. [7]
    Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis.
    Marx W, Lane M, Rocks T et al.Nutr Rev 2019meta-analysis · humanPMID 31135916◌ unreviewed
  8. [8]
    The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis.
    Khaksarian M, Behzadifar M, Behzadifar M et al.Psychol Res Behav Manag 2019meta-analysis · humanPMID 31118846◌ unreviewed
  9. [9]
  10. [10]
  11. [11]
  12. [12]
  13. [13]
  14. [14]
  15. [15]
    Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial.
    Lopresti AL, Smith SJ, Metse AP et al.J Clin Sleep Med 2020RCT · humanPMID 32056539◌ unreviewed
  16. [16]
  17. [17]
    Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials.
    Ayati Z, Yang G, Ayati MH et al.BMC Complement Med Ther 2020meta-analysis · humanPMID 33167948◌ unreviewed
  18. [18]
  19. [19]
  20. [20]
    Saffron Extract-Induced Improvement of Depressive-Like Behavior in Mice Is Associated with Modulation of Monoaminergic Neurotransmission.
    Monchaux De Oliveira C, Pourtau L, Vancassel S et al.Nutrients 2021preclinical · animalPMID 33799507◌ unreviewed
  21. [21]
    A simple practice guide for dose conversion between animals and human.
    Nair AB, Jacob SJ Basic Clin Pharm 2016reviewPMID 27057123◌ unreviewed
  22. [22]
    Prevention of Stress-Induced Depressive-like Behavior by Saffron Extract Is Associated with Modulation of Kynurenine Pathway and Monoamine Neurotransmission.
    Monchaux De Oliveira C, De Smedt-Peyrusse V, Morael J et al.Pharmaceutics 2021preclinical · animalPMID 34959434◌ unreviewed
  23. [23]
    Saffron extract interferes with lipopolysaccharide-induced brain activation of the kynurenine pathway and impairment of monoamine neurotransmission in mice.
    Monchaux de Oliveira C, Morael J, Guille A et al.Front Nutr 2023preclinical · animalPMID 37867499◌ unreviewed
  24. [24]
    Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach.
    Lin S, Li Q, Xu Z et al.Psychopharmacology (Berl) 2022preclinical · animalPMID 36169685◌ unreviewed
  25. [25]
    Saffron (Crocus Sativus L.), Combined with Endurance Exercise, Synergistically Enhances BDNF, Serotonin, and NT-3 in Wistar Rats.
    Akbari-Fakhrabadi M, Najafi M, Mortazavian S et al.Rep Biochem Mol Biol 2021preclinical · animalPMID 33969136◌ unreviewed
  26. [26]
    Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive-compulsive disorder.
    Georgiadou G, Tarantilis PA, Pitsikas NNeurosci Lett 2012preclinical · animalPMID 22985509◌ unreviewed
  27. [27]
    Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans.
    Corridori E, Salviati S, Demontis MG et al.Phytother Res 2025RCT · humanPMID 39754520◌ unreviewed
  28. [28]
    Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract.
    Orio L, Alen F, Ballesta A et al.Molecules 2020preclinical · animalPMID 32679643◌ unreviewed
  29. [29]
  30. [30]
    Effects of Supplementation with the Standardized Extract of Saffron (affron®) on the Kynurenine Pathway and Melatonin Synthesis in Rats.
    De la Fuente Muñoz M, Román-Carmena M, Amor S et al.Antioxidants (Basel) 2023preclinical · animalPMID 37627614◌ unreviewed
  31. [31]
    Use of a new saffron extract for the prevention of mood disorders related to depression
    Antonio Manuel INAREJOS GARCÍA, Marín PRODANOV PRODANOV, Amanda RAO et al.Patent ES2573542A1 · Pharmactive Biotech Products SL 2016patentnot peer reviewed◌ unreviewed
  32. [32]
    Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].
    Akhondzadeh S, Fallah-Pour H, Afkham K et al.BMC Complement Altern Med 2004RCT · humanPMID 15341662◌ unreviewed
  33. [33]
    Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence.
    Hasheminasab FS, Hajimonfarednejad M, Najibi SM et al.Health Sci Rep 2026meta-analysis · humanPMID 42057871◌ unreviewed
  34. [34]
    Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: A Case Report.
    Heidari Z, Daei M, Khalili H et al.Cardiovasc Hematol Disord Drug Targets 2022case report · humanPMID 35440328◌ unreviewed